Episode Details
Back to Episodes
Zachary Roberts: Building a Viable Off-the-Shelf CAR T
Description
Cancer immunotherapy evolved through decades of research, with watershed moments like checkpoint inhibitor approvals and the first CAR T trial results reshaping expectations. For Zachary Roberts, MD, PhD, witnessing CAR T-induced remissions as a Mass General resident convinced him of the field’s future and drew him from academia into drug development. Now as CMO and EVP of R&D at Allogene Therapeutics, he’s focused on the next inflection point: transforming CAR T into scalable, off-the-shelf therapies that could broaden access and extend impact beyond cancer to autoimmune disease.
Produced and hosted by Jonathan D. Grinstein, PhD
Audio mixed and mastered by Erick Ziegler
Brought to you by Inside Precision Medicine (SAGE Publishing)
Hosted on Acast. See acast.com/privacy for more information.